[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"juvenile-psoriatic-arthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:juvenile-psoriatic-arthritis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,74,101,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100523825","phase-3-a-study-to-assess-adverse-events-change-in-disease-activity-and-how-the-drug-moves-through-the-body-in-children-with-juvenile-psoriatic-arthritis-jpsa-receiving-subcutaneously-injected-risankizumab-or-adalimumab-100523825",false,"NCT06100744","A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab","Open-label, Randomized, Assessor-blinded, Efficacy, Safety, Tolerability, and Pharmacokinetics Study of Subcutaneous Risankizumab With an Adalimumab Reference Arm in Children With Active Juvenile Psoriatic Arthritis","Inclusion Criteria:\n\n* Diagnosis of juvenile psoriatic arthritis (jPsA) according to International League of Associations for Rheumatology criteria for at least 3 months prior to screening.\n* Active Disease in \\>= 3 joints at screening and at Baseline (swelling not due to deformity, or limitation of motion with pain, tenderness, or both) are eligible for inclusion in the study.\n* Have had an inadequate response (lack of efficacy after minimum 2-month duration of therapy at maximally tolerated dose), or intolerance to previous or current treatment with at least 1 of the following conventional synthetic disease-modifying antirheumatic drug (csDMARDs): methotrexate (MTX), sulfasalazine, leflunomide, or hydroxychloroquine.\n\nExclusion Criteria:\n\n* Have any other autoimmune disease, rheumatic disease (including systemic Juvenile idiopathic arthritis \\[JIA\\], rheumatoid factor-positive or rheumatoid factor-negative polyarticular JIA, extended oligoarticular JIA, persistent oligoarticular JIA, enthesitis-related arthritis, and undifferentiated JIA), or overlap syndrome.\n* Prior inadequate response to treatments in the anti-TNF or IL-23 inhibitor classes.","ALL","5 Years","17 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. PsA that begins before a patient's 16th birthday is called juvenile PsA (jPsA).This study will evaluate how safe risankizumab is for the treatment of psoriatic arthritis and to assess change in disease symptoms.\n\nRisankizumab is being studied for the treatment of jPsA and adalimumab is approved for the treatment of jPsA. Participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to receive adalimumab. Approximately 40 juvenile participants with jPsA will be enrolled at approximately 30 sites worldwide.\n\nParticipants will receive risankizumab and adalimumab as subcutaneous (SC) injections based on body weight. At the start of Period 1, participants are randomized to receive risankizumab or adalimumab for 24 weeks. Participants who respond to the study treatment received in Period 1, will continue to receive the same treatment in Period 2 for another 100 weeks. Those with worsening jPsA symptoms in Period 2 will be withdrawn from the study. Participants who receive adalimumab are followed for safety for 70 days after the last study treatment. Participants who receive risankizumab are followed for 140 days after the last study treatment.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.",[27],"Juvenile Psoriatic Arthritis",[27,29,30,31,32],"Psoriatic Arthritis","Risankizumab","ABBV-066","Adalimumab","RECRUITING","2026-06-29",{"date":36,"type":37},"2026-06-30","ACTUAL",{"date":39,"type":37},"2024-07-08",{"date":41,"type":21},"2028-10",{"name":43,"class":44},"AbbVie","INDUSTRY",33,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100582917","phase-3-a-study-to-evaluate-the-drug-levels-efficacy-and-safety-of-deucravacitinib-bms-986165-in-pediatric-participants-with-juvenile-psoriatic-arthritis-100582917","NCT06869551","A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis","A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Children and Adolescents From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis","Inclusion Criteria\n\n* Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA).\n* Participants must have at least three joints that are affected by arthritis.\n* Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems.\n\nExclusion Criteria\n\n* Participants must not have been diagnosed with JPsA before 5 years of age.\n* Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA,\n* Participants must not have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",{"count":54,"type":21},60,[24],"The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.",[27],[59,60,61,62,63],"Juvenile Psoriatic Arthritis (JPsA)","Juvenile Idiopathic Arthritis (JIA)","Pediatric PsA","Deucravacitinib","BMS-986165","2026-06-25",{"date":66,"type":37},"2026-06-26",{"date":68,"type":37},"2025-03-13",{"date":70,"type":21},"2031-03-04",{"name":72,"class":44},"Bristol-Myers Squibb",47,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100567437","phase-3-an-open-label-study-to-evaluate-the-pharmacokinetics-and-safety-of-bimekizumab-in-pediatric-study-participants-with-active-juvenile-idiopathic-arthritis-subtypes-enthesitis-related-arthritis-including-juvenile-onset-ankylosing-spondylitis-and-juvenile-psoriatic-arthritis-100567437","NCT06668181","An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis","Open-Label, Single-Arm Trial to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-Related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis","Inclusion Criteria:\n\n* Study participant must be 2 to \\\u003C18 years of age inclusive, at the Baseline Visit.\n* Study participants who have confirmed diagnosis of enthesitis-related arthritis (ERA; including juvenile-onset ankylosing spondylitis (JAS)) and\u002For juvenile psoriatic arthritis (JPsA) according to the juvenile-International League of Associations for Rheumatology (JIA-ILAR) classification criteria of at least 3 months duration prior to the Screening Visit.\n* Study participants who have active disease (ERA \\[including JAS\\] and\u002For JPsA) defined as having at least 3 active joints, each of which needs to be included in the joints assessed in the JADAS27, and for ERA at least 1 site of enthesitis at Baseline or documented by history.\n* Study participants with inadequate response (at least 1 month) or intolerance to at least 1 nonsteroidal anti-inflammatory drug (NSAID).\n* Study participants taking concomitant methotrexate or sulfasalazine are allowed to continue the medication if it has been used for the past 12 weeks with a stable dose for the 4 weeks prior to Baseline, with no change in dose for the first 16 weeks of treatment foreseen. (Note: prior or concomitant use of methotrexate or sulfasalazine is NOT required for study participation.)\n* Study participants with no concomitant use of second line agents such as disease-modifying and\u002For immunosuppressive drugs with the exception of methotrexate or sulfasalazine.\n* Body weight of ≥10kg.\n* Male and female.\n* A female study participant will be eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:\n\n  1. Not a woman of childbearing potential (WOCBP) OR\n  2. A WOCBP who agrees to follow the contraceptive guidance during the Initial Treatment Period, the Open-label Extension (OLE) Period, and for at least 20 weeks after the final dose of investigational medicinal product (IMP; ie, the Safety Follow-up (SFU) Period)\n* Capable of giving\u002Fhaving parent(s) or legal representative provide signed informed consent\u002Fassent (where appropriate), which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and assent and in this protocol.\n\nExclusion Criteria:\n\n* Study participants fulfilling any International League of Associations for Rheumatology (ILAR) diagnostic juvenile idiopathic arthritis (JIA) category other than enthesitis-related arthritis (ERA; including juvenile-onset ankylosing spondylitis (JAS)) and\u002For juvenile psoriatic arthritis (JPsA).\n* Study participant has history of inflammatory bowel disease (IBD) or signs\u002Fsymptoms suggestive of IBD.\n* Study participant has active uncontrolled uveitis.\n* Study participant has history of active tuberculosis (TB) unless successfully treated, latent TB unless prophylactically treated.\n* Study participant has had major surgery (including joint surgery) within the 3 months prior to the Baseline Visit or has planned major surgery within 6 months after entering the study.\n* Study participant has laboratory abnormalities at Screening defined in the Protocol.\n* Study participant has an active infection or history of infections (such as serious infection, chronic infections, opportunistic infections, unusually severe infections).\n* Study participant has received drugs listed in the protocol outside the specified timeframes relative to the Baseline Visit or receives prohibited concomitant treatments.\n* Study participant had previous therapy with bimekizumab or prior treatment with other IL-17 biologic response modifier.\n* Study participant had prior treatment with more than one biologic response modifier (other than an IL-17).\n* Presence of active suicidal ideation, or positive suicide behavior.\n* Study participant has been diagnosed with severe depression in the past 6 months.","2 Years","18 Years",{"count":20,"type":21},[24],"The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.",[87,27],"Enthesitis-related Arthritis",[89,90],"Arthritis","Bimekizumab","2026-06-18",{"date":93,"type":37},"2026-06-22",{"date":95,"type":37},"2025-03-11",{"date":97,"type":21},"2030-07-31",{"name":99,"class":44},"UCB Biopharma SRL",23,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":18,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100573819","phase-1-study-to-evaluate-the-pharmacokinetics-pk-safety-and-tolerability-up-to-6-years-of-intravenous-iv-secukinumab-in-pediatric-participants-with-juvenile-psoriatic-arthritis-jpsa-100573819","NCT06751238","Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).","An Open-label, Multicenter Study to Evaluate Pharmacokinetics, Safety and Tolerability up to 6 Years of Intravenous Secukinumab Infusions in Pediatric Participants With Juvenile Psoriatic Arthritis","Key Inclusion Criteria:\n\n* Participants parent's or legal representative(s) written informed consent and child's assent, if appropriate, must be obtained before any study related activity or assessment is performed. Of note, if the participant reaches age of consent (as per local law) during the study, they will also need to sign the corresponding study ICF (Informed Consent Form).\n* Males and females ≥2 years old to \\\u003C18 years old at the time of screening.\n* Confirmed diagnosis of JPsA according to the modified International League of Associations for Rheumatology (ILAR) classification criteria that must have occurred at least 6 months prior to screening.\n* Active JPsA disease defined as ≥3 active joints (swollen or if not swollen must be both tender and limited range of motion) at baseline (BSL).\n* Inadequate response (≥1 month) or intolerance to ≥1 Non-Steroidal Anti-Inflammatory Drug (NSAID) at screening.\n* Inadequate response (≥2 months) or intolerance to ≥ 1 Disease Modifying Anti-Rheumatic Drug (DMARD) at screening.\n* Concomitant use of the following second-line agents such as disease-modifying and\u002For immunosuppressive drugs to treat the JPsA will be allowed:\n\n  * Stable dose of methotrexate (MTX) (maximum of 20 mg\u002F m2 BSA\u002F week) for at least 4 weeks prior to the BSL visit, with folic\u002Ffolinic acid supplementation (according to standard medical practice of the center).\n  * Stable dose of an oral corticosteroid (CS) at a prednisone equivalent dose of \\\u003C0.2 mg\u002Fkg\u002Fday or up to 10 mg\u002Fday maximum, whichever is less, for at least 7 days prior to BSL.\n  * Stable dose of no more than one NSAID for at least 1 week prior to BSL.\n\nKey Exclusion Criteria:\n\n* Participants with body weight less than 10 kg at screening.\n* Use of other investigational drugs within 4 weeks or 5 half-lives of BSL, or until the expected pharmacodynamic effect has returned to BSL, whichever is longer.\n* History of hypersensitivity to study drug or its excipients or to drugs of similar chemical classes.\n* Participants with active inflammatory bowel disease or active uveitis at screening or BSL.\n* Fulfilling diagnostic criteria for any International League of Associations for Rheumatology (ILAR ) juvenile idiopathic arthritis (JIA) category other than JPsA at BSL.\n* Participants treated with prohibited medication\n* Participants taking any non-biologic DMARD at screening except for MTX.\n* Any medical or psychiatric condition which, in the investigator's opinion, would preclude the participant from adhering to the protocol or completing the study per protocol.\n\nOther inclusion\u002Fexclusion criteria may apply",{"count":109,"type":21},20,[111],"PHASE1","The purpose of this study is to determine the PK, safety and tolerability of multiple doses of intravenous (i.v.) secukinumab in pediatric participants with JPsA",[27],[115,116,117,118,119,120],"Pediatric","JPsA","Pharmacokinetic (PK)","safety","Intravenous (i.v.)","Secukinumab","2026-06-01",{"date":123,"type":37},"2026-06-02",{"date":125,"type":37},"2025-09-24",{"date":127,"type":21},"2032-12-01",{"name":129,"class":44},"Novartis Pharmaceuticals",8,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":158},"100498191","phase-3-a-study-of-apremilast-in-children-with-oral-ulcers-associated-with-behets-disease-or-juvenile-psoriatic-arthritis-100498191","NCT05767047","A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis","A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of Age or Older With Oral Ulcers Associated With Behçet's Disease or 5 Years of Age or Older With Juvenile Psoriatic Arthritis","Inclusion Criteria:\n\n* Informed consent \u002F assent obtained\n* Must have completed Week 52 on treatment on core study and must be \\\u003C 18 years of age at the time the informed consent document is signed\n* Age and sex specific body mass index (BMI) no lower in range than the 5th percentile on Centers for Disease Control (CDC growth chart) at enrollment\n* Willing to adhere to study visit schedule and protocol requirements\n* Must have acceptable benefit\u002Frisk for continued treatment with apremilast\n\nExclusion Criteria:\n\n* Answer \"yes\" to any question on C-SSRS at Week 52 visit of core study\n* Scheduled surgery or other interventions that would interrupt study participation\n* Female participants of childbearing potential unwilling to use protocol specified method of contraception during treatment and for 30 days after last dose\n* Female participants planning to become pregnant while on study through 30 days after last dose\n* Female participants of childbearing potential with positive pregnancy test at Week 0\n* Known sensitivity to any products to be administered during dosing",{"count":139,"type":21},48,[24],"The primary objective of this study is to evaluate the long-term safety of apremilast in subjects 2 years of age or older with oral ulcers associated with Behçets disease or 5 years of age or older with active juvenile psoriatic arthritis that have completed Study 20190530 or Study 20190529.",[143,27],"Behçet's Disease",[145,143,27,146,147,148],"Oral Ulcers","Apremilast","AMG 407","Otezla","2025-11-26",{"date":151,"type":37},"2025-12-01",{"date":153,"type":37},"2023-03-23",{"date":155,"type":21},"2036-03-17",{"name":157,"class":44},"Amgen",7]